TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval (the"Clinical Trial Approval") for its R520A, a mRNA COVID-19 vaccine ("R520A"), from the Food and Drug Administration ofthe P...
TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has recently received the clinical trial approval (the "Clinical Trial Approval") for its recombin...
TAIZHOU, China, April 13, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has received approval from the Ministry of Health and Prevention of theUnited Arab Emirates ("U...
TAIZHOU, China, April 11, 2022 /PRNewswire/ --?The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on April 9, 2022, the Company has received the European Union (EU) Qualified Pe...
Offer Price of HK $24.80 per H Share To Raise Proceeds Up to HK$765 Million Focus on the R&D of HPV Vaccine Candidates Focus on In-house Research and Development of Novel Vaccines TAIZHOU, China, March 21, 2022 /PRNewswire/ -- The China-based novel vaccines company -Jiangsu Recbio Technology Co....